Market and Product-Safety Consequences of a 0.4 mg Threshold

This page is analysis and advocacy — it is not legal advice

Read this before you read anything else on the page. What follows is a research and policy brief. It is written to be used by regulators, legislators, counsel and industry researchers as an argument, and the argument is stated at full strength because a hedged brief is useless to the people who need it. It is not a legal opinion, it is not a clearance, and it is not advice to you. Three things make that more than a formality. First, cannabinoid law varies enormously by state: a compound that is lawful under federal law can be a felony in the jurisdiction where you live, ship, store or sell, and state analogue statutes, total-intoxicant caps and compound-by-name bans operate independently of the federal scheme described here. Second, this area of law is changing quickly — the federal definition of hemp itself was rewritten in late 2025 with a delayed effective date, state legislatures have moved in both directions in every recent session, and agency positions have shifted. Anything written here can be overtaken by an amendment, a rule, or a decision. Third, an argument that a substance is not a controlled substance analogue is a defence, not a permission: it is something a defendant says after being charged, and the fact that it is a good argument does not mean nobody will be charged. Do not make a business decision, a product decision or a personal decision on the basis of this page. Get your own lawyer, licensed in your own jurisdiction, and give them the actual facts. This page is a policy forecast, not a prediction with evidentiary standing, and certainly not business advice. The market figures in it are industry estimates and are marked as contested.

• Not legal advice, and no lawyer-client relationship arises from reading it.
• Federal lawfulness does not imply state lawfulness — check your own state, and the states you ship to.
• The law described here is in motion; a delayed federal effective date sits in the middle of it.
• A strong non-analogue argument is a defence to a charge, not immunity from one.
• Nothing here is medical advice either, and nothing here is an endorsement of using any compound.

Market scale — industry estimates, and they are contested contested

The figures that circulate in this debate are 13 to 28 billion dollars of hemp-derived cannabinoid economic activity nationally and approximately 8 billion dollars in Texas alone. They should be used, and they should be labelled for what they are: estimates produced by trade associations and industry analysts, advanced in legislative advocacy, with methodologies that are not published in a form this shelf has checked. The range itself — a factor of more than two at the national level — indicates how much definitional choice is doing the work, because "economic activity" can mean retail sales, or gross receipts across the supply chain, or an output multiplier including induced effects, and those differ by large factors. The Texas figure was quoted extensively in the 2025 Senate Bill 3 debate and appears in the governor's veto discussion of the industry's size. The honest position for a research institute is that the market is large enough that prohibition has real economic consequences, that the specific numbers are advocacy figures rather than measurements, and that a brief which stakes its credibility on an unverifiable 28 billion dollar figure is easier to dismiss than one which says "on industry estimates in the low tens of billions, and here is why the number is uncertain".

Contested — caveat. CONTESTED AND ADVOCACY-SOURCED. The 13 to 28 billion dollar national and 8 billion dollar Texas figures are industry and trade-association estimates circulated in legislative debate. No independent verification, and no published methodology, was obtained in this pass. Do not present them as measured data.

Sources: Hemp trade associations 2025* · Office of the Governor of Texas (Greg Abbott) 2025 · Texas Legislature 2025

The arithmetic contested

The threshold's effect does not require a forecast; it requires division. Typical hemp-derived products on the market before the provision carry 5 to 10 mg of total THC in a beverage, 10 to 25 mg in a gummy, and 50 to 100 mg in a tincture bottle. The new limit is 0.4 mg per container, where container is the innermost vessel in direct contact with the product. A 10 mg beverage is 25 times the limit. A thirty-piece jar of 10 mg gummies is 300 mg in the container, which is 750 times the limit. A 100 mg tincture bottle is 250 times it. Reformulation to comply is not a matter of reducing potency; for a multi-serving package it means a per-piece quantity in the region of 13 micrograms, which is not a low dose of an intoxicant but the absence of one, and below the practical limit of homogeneous dosing for most confection processes. The conclusion is arithmetic rather than rhetorical: the threshold does not regulate the existing product category, it eliminates it. That is a legitimate legislative aim and it is very likely the actual aim. It should simply be analysed as elimination and not as a potency cap, because the policy consequences of eliminating a category are different from those of capping it.

Contested — caveat. The typical-potency figures are the operator's source's characterisation of the market and are consistent with widely marketed products, but they are not drawn from a surveyed dataset. The arithmetic against the threshold is exact; the inputs are representative rather than measured.

Sources: United States Congress 2025 · Congressional Research Service 2025 · Hemp trade associations 2025*

Pathway one: displacement to unregulated supply, as a product-safety consequence

The economic form of this argument is familiar and is usually the only form it is given: consumers of a legal taxed product move to an illegal untaxed one, and revenue and compliance are lost. That is true and it is the less important half. The consequential half is a product-safety argument, and it should be made in those terms because that is the argument a health regulator is obliged to weigh. What is displaced is not consumption; it is testing. The hemp-derived market that developed after 2018 developed, unevenly but substantially, a certificate-of-analysis culture: potency assays on finished product, residual-solvent panels, heavy metals, pesticides, microbials, and batch identification — driven by state consumable-hemp programmes, by retailer requirements and by the reputational exposure of a named brand. Unregulated supply carries none of that. The specific hazards are documented and they are not speculative. Converted-cannabinoid material can carry reaction by-products and isomeric impurities that are not the labelled compound and are not characterised toxicologically. Residual solvent and residual catalyst can remain in material produced without analytical control. Products sold as one cannabinoid can contain another, or contain a synthetic cannabimimetic on an unrelated scaffold, which is the specific substitution that produced the severe-toxicity pattern of the synthetic-cannabinoid era. Unlabelled or mislabelled potency removes the possibility of titration. Every one of those hazards is worse in an untested channel than in a tested one, and the displacement is therefore from a channel where a buyer can read a certificate to one where there is nothing to read. Whatever view a regulator takes of intoxicating hemp products, the transition from tested to untested supply is a public-health cost of the policy and belongs on the ledger.

• What is displaced is testing, labelling and traceability — not demand.
• Converted material can carry uncharacterised isomeric and reaction by-products; a COA is how a buyer sees that.
• Residual solvent and catalyst are analytical findings; without an assay they are invisible.
• Compound substitution — an unrelated cannabimimetic sold as a cannabinoid — is the documented severe-harm pattern.
• Unlabelled potency removes titration, which is the main tool a user has for avoiding an overdose.

Sources: United States Congress 2025 · Andrews R 2022 · Kiselak TD 2020 · Hemp trade associations 2025*

Pathway two: substitution toward more potent compounds, and the irony in it contested in vitro

A threshold expressed as a quantity of a named analyte class, with no reference to potency, creates a gradient that points the wrong way. Compliance is measured in milligrams of total THC per container. Intoxication is a matter of receptor occupancy. A compound with an order of magnitude greater affinity and efficacy at CB1 delivers the same subjective effect from an order of magnitude less mass — so for any compound outside the measured class, the tighter the mass threshold, the greater the advantage of potency. That is not a loophole in the drafting; it is a property of regulating mass rather than effect. The reported affinity of THCP at CB1 is roughly 33 times that of delta-9 THC, from a single 2019 study, and the whole homolog series exists precisely because potency tracks side-chain length. The predictable market response to a milligram cap is therefore a shift of interest toward compounds where milligrams are not the binding constraint, and the plant offers a large number of them: the classes are numerous, the side-chain lengths several, the ring closures and double-bond positions several more. State the irony plainly, because it is the strongest single argument in this brief addressed to a regulator: a potency-blind quantity threshold does not reduce the potency of what is available, it selects for potency. That was, until recently, an assertion on this page — a mechanism argued from first principles, with nothing behind it but the plausibility of the reasoning. It is not an assertion any more. The treadmill page sets out the same mechanism as three documented precedents: the synthetic cannabinoids from the JWH naphthoylindoles through to the indazole carboxamides, the phenethylamines from 2C-B through to the NBOMe series, and the opioids from heroin through fentanyl and its analogues to the nitazenes — each one recorded turn by turn in the Federal Register by the agency that did the scheduling, and each one moving up the potency curve rather than out of existence. A regulator who wants to dispute the substitution prediction now has to dispute thirty years of the government's own scheduling record, not a paragraph of reasoning. And add the honest qualification, because it matters: a designation power keyed to similar effects, of the kind section 781 contains, is the obvious answer to this, and if exercised broadly it closes much of the gap. The argument is against the threshold as a mechanism, not a prediction that the mechanism cannot be supplemented.

Contested — caveat. The 33-fold figure for THCP is from a single 2019 in-vitro and mouse study and has not been independently replicated in the form quoted. The substitution argument does not depend on the exact multiple, only on the direction; but the multiple should not be quoted as established.

Sources: Citti C 2019 · Linciano P 2019 · Radwan MM 2021 · ElSohly MA 2005 · United States Congress 2025 · Adams R 1949 · Drug Enforcement Administration 2011 · United States Congress 2012 · Drug Enforcement Administration 2014 · Drug Enforcement Administration 2023 · Beletsky L 2017

Pathway three: the enforcement gap, stated as an enforcement gap

The third consequence is addressed to regulators and it is a statement about enforceability. The precursor chemicals involved in cannabinoid interconversion are, with limited exceptions, not controlled substances and not watched: the plant-derived starting cannabinoids have been lawful commodities in commerce since 2018 and are held in quantity in warehouses across the country, and the other reagent classes involved are ordinary articles of commerce with large legitimate markets. The transformations themselves are old and well documented — the isomerisation of cannabidiol to the tetrahydrocannabinols appears in the literature from Adams in 1940 and 1941, in Gaoni and Mechoulam in 1966, in the Webster, Sarna and Mechoulam patent of 2008, in the review by Bloemendal and colleagues in 2020, and in the forensic study by Kiselak and colleagues in 2020 — and they are chemically undemanding. The regulatory consequence of those two facts together is that a threshold applied to finished articles at retail does not constrain the inputs, and cannot be enforced at the point where the inputs are held. That is the argument, and it is an argument about the design of a rule: a rule whose binding constraint is downstream of uncontrolled, widely held, abundant inputs will be evaded at low cost, and a regulator choosing between instruments should know that before choosing. This shelf will not go further than that. It does not describe what any conversion involves, it does not identify anything to obtain, and it does not treat the gap as a commercial opportunity. The operator's source document frames this third pathway as a product category; that framing is not adopted here, because the legitimate content of the point is entirely exhausted by the enforceability argument, and the rest is a recipe.

Sources: Adams R 1940 · Adams R 1941 · Gaoni Y 1966 · Webster GRB 2008 · Bloemendal VRLJ 2020 · Kiselak TD 2020 · United States Congress 2025 · Drug Enforcement Administration 2020

The general defect: regulating the labelled analyte rather than the intoxicant

The three pathways share a single structural cause, and naming it is more useful than listing them. Every federal instrument in this area has defined its object by analyte identity and its limit by quantity of that analyte. The 2018 definition named delta-9 THC. The 2025 provision names total tetrahydrocannabinols including THCA, which is a substantial improvement because it closes the decarboxylation gap, and adds a designation power, which is a further improvement because it is not a closed list. But the limit is still a quantity of a defined analyte set, measured in the finished article. A compound outside the set is outside the limit until designated; a compound inside the set but far more potent per milligram is under-constrained by a mass limit; and a rule enforced on the finished article does not reach the inputs. What would regulate the intoxicant rather than the analyte is a potency-weighted or effect-referenced standard — a THC-equivalent unit, with equivalence factors set by receptor pharmacology and revised as compounds are characterised — together with a licensing regime that constrains conversion capacity rather than retail content, and mandatory analytical verification of the finished product against the label. That is a harder instrument to draft and it requires analytical and pharmacological capacity the enforcement system does not currently have. It is also the only form of rule that is not structurally behind the chemistry, and it is what a research institute is actually in a position to help build.

• A potency-weighted THC-equivalent unit, with factors from receptor pharmacology, revised as compounds are characterised.
• Licensing and inspection of conversion capacity, which is where the inputs actually are.
• Mandatory finished-product verification against the label, by accredited method, with the assay defined in the rule.
• Reference-standard availability for novel and homolog cannabinoids, without which none of the above is measurable.

Sources: United States Congress 2025 · United States Code 2018 · Drug Enforcement Administration 2020 · Citti C 2019 · Radwan MM 2021

The conclusion of the argument

Stated in the operator's form, because it is the right form: the chemistry cannot be prohibited, only the legal and tested market can be destroyed. The transformations at issue are eighty-five years old and published in the open literature of the American Chemical Society, the Royal Society of Chemistry and the United States patent record; the plant makes over a hundred cannabinoids and the homolog series among them; the combinatorial space of structures is far too large to enumerate. None of that is affected by a definition. What a definition can do, and what a 0.4 mg per-container threshold does, is remove the part of the supply chain that tests its products, labels its potency, identifies its batches, answers to a state licensing authority and can be sued under its own brand name. The argument of this shelf is therefore not that intoxicating hemp products should be unregulated. It is that the instrument chosen regulates the measurable rather than the harmful, and that the predictable consequence is the same quantity of intoxicant consumption through a channel with no analytical layer in it.

Sources: Adams R 1940 · Gaoni Y 1966 · Crombie L 1988 · Razdan RK 1974 · Bloemendal VRLJ 2020 · Radwan MM 2021 · ElSohly MA 2005 · United States Congress 2025

The counter-argument a regulator would make, stated fairly

A brief that does not survive contact with the other side is not worth filing, and there is a serious answer to everything above. It runs as follows, and it is not obviously wrong. Reducing legal availability reduces aggregate consumption regardless of enforcement gaps, because availability is not binary: the demand that reaches a gas-station cooler at a convenience price point is far larger than the demand that will seek out an illicit supplier, and the difference is disproportionately among young and occasional users. Displacement is not complete, and partial displacement can be a net public-health gain even with the safety costs on the other side. The safety argument, moreover, cuts both ways: the tested channel whose loss this shelf laments came into existence by exploiting a drafting gap, sold psychoactive products with no federal product-safety framework, no pre-market review and no age-verification requirement, through retail channels not licensed to sell intoxicants, and the certificate-of-analysis culture within it is real but uneven and includes a documented incidence of inaccurate certificates. Calling that a regulated market overstates it. The enforcement-gap argument proves too much: every prohibition has an evasion route with uncontrolled inputs, and the observation that a rule can be evaded is not an argument that it should not be made — alcohol prohibition of distillation inputs is not the test of alcohol regulation. And the substitution-toward-potency argument is answered by the designation authority, which exists precisely so that the rule need not chase compounds one at a time. A regulator holding these points is not being unreasonable. The strongest honest position for this shelf is therefore narrower than the operator's source claims: not that the policy will fail, but that its product-safety cost is real, is being under-counted, and can be substantially mitigated by instrument design — potency-weighted equivalence, licensed conversion capacity, mandatory verified labelling — that the current instrument does not use.

• Reduced availability reduces aggregate use even where evasion is possible; availability is a gradient, not a switch.
• The displaced market was itself only partly regulated, with no federal product-safety framework and uneven COA quality.
• Evadability is not by itself an argument against a prohibition.
• The similar-effects designation power answers much of the substitution objection.
• The defensible claim is that the safety cost is under-counted and mitigable by better instrument design, not that the policy must fail.

Sources: United States Congress 2025 · Congressional Research Service 2025 · Andrews R 2022 · Drug Enforcement Administration 2020 · Hemp trade associations 2025*